Sign In
Buy IDYA
$28.40
+0.530 (+1.90%)
At Close: Jun 03, 2026
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
06:00am, Tuesday, 28'th May 2024
Over 18-years at leading life sciences and strategy consulting companies, including Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey & Company SOUTH SAN FRANCISCO, Calif. , M
~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment Median tumor shrinkage (maximum volume change) of ~39% after 6 months Clinic
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
06:00am, Tuesday, 07'th May 2024
ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored tria
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
06:00am, Wednesday, 01'st May 2024
SOUTH SAN FRANCISCO, Calif. , May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 26'th Apr 2024
SOUTH SAN FRANCISCO, Calif. , April 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted thera
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
10:05am, Wednesday, 24'th Apr 2024
Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET SOUTH SAN FRANCISCO, Calif. , April 24
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial respon
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 05'th Apr 2024
SOUTH SAN FRANCISCO, Calif., April 5, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
06:00am, Monday, 01'st Apr 2024
SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
�Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cance
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
06:00am, Monday, 04'th Mar 2024
SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announ
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
06:00am, Tuesday, 20'th Feb 2024
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study Targetin
Ideaya Biosciences: A Strong Bet In Targeted Oncology
12:56pm, Friday, 16'th Feb 2024
IDEAYA Biosciences' stock has increased by 57% since September, outperforming the S&P 500. PRMT5 inhibitors have gained attention in the biotech industry, with Bristol Myers paying $5.8 billion, in pa
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
06:00am, Thursday, 01'st Feb 2024
SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:00am, Friday, 26'th Jan 2024
SOUTH SAN FRANCISCO, Calif. , Jan. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap
